 | |
| Company type | Public limited company |
|---|---|
| LSE:IXI | |
| Industry | Data analytics for clinical research |
| Founded | 2004 |
| Founders | Professors Derek Hill,Daniel Rueckert, David Hawkes and Jo Hajnal |
| Headquarters | London ,United Kingdom |
Area served | Worldwide |
Key people | Charles Spicer (Chairman) Giulio Cerroni (CEO) |
| Website | https://ixico.com/ |
IXICO plc is a UKclinical research firm that providesneuroimaging and digital biomarker analytics tobiopharmaceutical firms conducting clinical trials into neurological diseases such asAlzheimer's disease (AD) andHuntington's disease (HD).
IXICO was incorporated in 2004[1] as a spin-out from three London academic institutions:Imperial College London,University College London andKing's College London.[2] The initial 3-year research project was called 'Information eXtraction from Images' (hence the IXI name), and funded by theUK e-science core and other industry partners.[3]
In October 2013, IXICO entered theAlternative Investment Market (AIM) of the London Stock Exchange through areverse takeover of defunct pharmaceutical drug company Phytopharm.[4]
Phytopharm was a Britishpharmaceutical company, incorporated on 28 November 1995. Briefly known as Lawnhale, it changed its name to Phytopharm in March 1996[5] and listed on the London Stock Exchange on 25 April of the same year (LSE:PYM).[6] It announced plans for a secondary listing onNASDAQ in 2004 (NASDAQ:PHYOF).[7] By 2012, the Phytopharm group consisted of a parent company, Phytopharm plc, a wholly owned trading subsidiary, Phytotech Limited, and a dormant subsidiary, Phytodevelopments Limited.[8]
Amongst other activity, Phytopharm raised funds for research into treatment ofParkinson's disease (PD) from sources including theMichael J Fox Foundation,[9] but the company collapsed in 2013 following the failure of its main PD drug (Cogane) during clinical trials.[10] Its shares were suspended from trading on 20 May 2013.[11][12]
